 Avadel Pharmaceuticals plc AVDL, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020, to provide a corporate update and discuss the Companys financial results for the first quarter ended March 31, 2020. A live audio webcast can be accessed by visiting the investor relations section of the Companys website, Avadel Pharmaceuticals plc AVDL is an emerging biopharmaceutical company. 